Plaque Psoriasis

These real-world findings on tildrakizumab’s use among patients with moderate-to-severe plaque psoriasis highlight the drug’s efficacy regarding high burden symptoms.

In this analysis, disparities associated with race, old age, socioeconomic differences, and rural residence were highlighted as examples.

These findings made comparisons between clinical outcomes of interclass and intraclass switching of biologic treatments among individuals with psoriasis.

These data were identified to expand upon existing information regarding treatment options for facial psoriasis and/or genital psoriasis.

A panel of dermatologists have a comprehensive discussion on exciting developments in the treatment of plaque psoriasis, focusing on treatment approaches, patient monitoring strategies, and recent clinical trial data.

Bruce Strober, MD, PhD, and Linda Stein Gold, MD, provide clinical insights on long-term safety data for deucravacitinib and selecting the right treatment for the right patient.

Dermatologists have a comprehensive discussion on systemic therapies for the treatment of plaque psoriasis, covering monitoring practices, and long term efficacy data for novel oral agent deucravacitinib.

These data suggest that quality of life, assessed by DLQI, may be implemented in determining treatment efficacy among patients with psoriasis.

Linda Stein Gold, MD, and Bruce Strober, MD PhD, discuss classification and monitoring practices for patients with plaque psoriasis.

These data, resulting from a post-hoc analysis, highlighted the musculoskeletal, skin, and nail outcomes among patients with psoriasis and PsA.

This analysis among Japanese patients highlights the potential of apremilast for psoriasis patients not responding to topical therapy who may have limited systemic treatment options.

A meta-analysis shows hand eczema has a moderate-to-severe impact on quality of life and anxiety.

In this systematic review and meta-analysis, the clinical efficacy of glucagon-like peptide 1 receptor agonists was evaluated.

These data highlight rates of biologic treatment discontinuation in younger adult patients versus elderly patients, with comparisons drawn between IL-23 inhibitors and IL-17 inhibitors as well.

These data do not support the idea that interferon-beta works as a trigger for psoriasis, though it may have a different influence on psoriasis among those with MS versus those without MS.

These data resulted from a new meta-analysis in which biologic therapies were shown to be less effective among psoriasis patients with clinical characteristics such as age and BMI.

These data may require large-scale studies to duplicate the findings, evaluating individuals with psoriasis who had PPM for IE antibiotic prophylaxis.

These data suggest that those with psoriasis maintain an innate psychological vulnerability, indicating the necessity of addressing mental well-being in the disease’s management.

Mona Shahriari, MD, discusses how she foresees the role of nonsteroidal topical creams growing within the management of plaque psoriasis.

Mona Shahriari, MD, discusses the evolving role of nonsteroidal topical options the management of plaque psoriasis.

These multicenter, retrospective data highlight the use of guselkumab after discontinuing ustekinumab treatment up to 156 weeks of use.

A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

These findings highlight potential drawbacks of treating psoriasis with phototherapy versus anti-TNFα therapy, though additional research is needed.